New leadership and reorganization will foster the next
chapter of growth and enhance business operations to best support
evolving client and CRO partner needs on a global scale.
MALVERN,
Pa., Oct. 29, 2024 /PRNewswire/ -- Resolian, a
leading global bioanalytical and analytical sciences partner
supporting drug development and multi-regional clinical trials,
today announced several leadership changes as the company expands
its global footprint and operational capabilities. Rob Stachlewitz will join Resolian as Chief
Executive Officer (CEO), while current CEO Pat Bennett will transition into the newly
created role of Chief Business Officer and President of Scientific
Affairs. In addition, the board has appointed Honggang Bi as Chairman.
Backed by Boston-based private
equity firm Ampersand Capital Partners and KKR's Health Care
Strategic Growth strategy, Resolian has experienced rapid expansion
over the past several years, positioning itself as a premier global
bioanalytical contract research organization (CRO). This included
the acquisition of US based Alliance Pharma, Inc. in Malvern, PA, the addition of UK-based Drug
Development Solutions in July 2022,
the establishment of a state-of-the-art bioanalytical lab in
Brisbane, Australia in
December 2022 to form Resolian, and
the acquisition of China-based
Denali MedPharm in November 2023,
which expanded Resolian's operations to four continents.
"It's an honor to be appointed Chairman of Resolian. I am
excited to work alongside Rob, Pat, the Ampersand and KKR teams,
and our nearly 500 dedicated global employees. Resolian is an
innovative, global, bioanalytical and analytical CRO. I am
confident we have the leadership, vision and dedicated
quality-driven team to execute our clients' therapeutic programs,"
said Honggang Bi. Newly-appointed Chairman Honggang Bi posesses a more than 30 year
illustrious career with Pfizer, Covance and Labcorp, leading their
drug development operations across multiple geographies.
Incoming CEO Rob Stachlewitz
joins Resolian with an impressive track record, having most
recently served as Corporate Vice President and General Manager at
Charles River, where he oversaw their largest site. Rob brings 15
years of pharmaceutical R&D experience, having held key roles
at Boehringer Ingelheim, Abbott Laboratories, and Procter &
Gamble. As CEO, Rob will guide
Resolian through its next phase of strategic growth, enhancing its
operational capabilities and global presence.
"With Rob's extensive background shepherding life science
businesses and teams on a global scale, we are confident that he
will lead Resolian to new heights as we continue to expand our
bioanalytical operations," added Honggang
Bi. Rob holds a PhD from the University of North Carolina at Chapel Hill and a
B.S. from Michigan State University. He
is a respected leader in the scientific community, having
chaperoned drugs through the development process and contributed
over 30 publications.
Pat Bennett, who has led Resolian
for nearly three years, has been instrumental in strategically
positioning and steering the organization through a dynamic and
transformative period, harmonizing operations, and driving global
expansion. As Chief Business Officer and President of Scientific
Affairs, Pat will focus on growing new service capabilities and
enhancing customer relationships, leveraging his 30+ years of
experience in bioanalytical sciences and business development. Pat
will also oversee several critical functions to foster client
collaboration and synergies across the Resolian team.
"We are incredibly grateful for Pat's leadership during a
pivotal time in Resolian's history," said Dave Patteson, Partner, Ampersand Capital
Partners. "As he transitions into his new role, Pat will continue
to make critical contributions to Resolian's future growth and
innovation. The combined leadership of Honggang, Rob and Pat is
unrivaled in the bioanalytical CRO industry. The Resolian team will
provide industry leading bioanalytical services to clients for
their drug development projects across all major geographies."
About Resolian
Resolian (formerly Alliance Pharma
Inc., Drug Development Solutions Ltd. and Chongqing Denali
Medpharma, Ltd.) is a leading global research laboratory that
provides specialized services in GxP and nonregulated bioanalysis,
drug metabolism/pharmacokinetics (DMPK), and GMP CMC analytical and
materials science. Nearly 500 experts across the U.S., U.K., and
Australia deliver quality results,
ensuring the highest standard of regulatory compliance throughout
the drug development continuum. Resolian's dedicated laboratories
are equipped with state-of-the-art technology that meet the needs
of preclinical and clinical programs at any scale.
About Ampersand Capital Partners
Ampersand Capital
Partners, founded in 1988, is a middle-market private equity firm
with $3 billion of assets under
management, dedicated to growth-oriented investments in the
healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a
unique blend of private equity and operating experience to build
value and drive long-term performance alongside its portfolio
company management teams. Ampersand has helped build numerous
market-leading companies across each of the firm's core healthcare
sectors. For additional information,
visit AmpersandCapital.com or follow us
on LinkedIn.
About KKR
KKR is a leading global investment firm that
offers alternative asset management as well as capital markets and
insurance solutions. KKR aims to generate attractive investment
returns by following a patient and disciplined investment approach,
employing world-class people, and supporting growth in its
portfolio companies and communities. KKR sponsors investment funds
that invest in private equity, credit and real assets and has
strategic partners that manage hedge funds. KKR's insurance
subsidiaries offer retirement, life and reinsurance products under
the management of Global Atlantic Financial Group. References to
KKR's investments may include the activities of its sponsored funds
and insurance subsidiaries. For additional information about KKR
& Co. Inc. (NYSE: KKR), please visit KKR's website at
www.kkr.com. For additional information about Global Atlantic
Financial Group, please visit Global Atlantic Financial Group's
website at www.globalatlantic.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/resolian-appoints-rob-stachlewitz-as-ceo-honggang-bi-as-chairman-of-the-board-and-pat-bennett-as-chief-business-officer-and-president-of-scientific-affairs-302289255.html
SOURCE Resolian